Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma

References

• Swerdlow S, Campo E, Harris NE, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC press, Lyon 2008.
   Google Scholar
• Sandes AF, de Lourdes Chauffaille M, Oliveira CR, et al. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom 2014;86:98–105.
   PubMed Web of Science ®Google Scholar
• Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res 2009;33:1212–1216.
   PubMed Web of Science ®Google Scholar
• Kelemen K, Peterson LC, Helenowski I, et al. CD23 + mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol 2008; 130:166–177.
   PubMed Web of Science ®Google Scholar
• Barna G, Reiniger L, Tatrai P, et al. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol 2008;26:167–170.
   PubMed Web of Science ®Google Scholar
• Espinet B, Salaverria I, Bea S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 2010;49:439–451.
   PubMed Web of Science ®Google Scholar
• Moreau EJ, Matutes E, A’Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378–382.
   PubMed Web of Science ®Google Scholar
• Tandon B, Peterson L, Gao J, et al. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas. Mod Pathol 2011;24:1433–1443.
   PubMed Web of Science ®Google Scholar
• Walther N, Ulrich A, Vockerodt M, et al. Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt’s lymphoma. Am J Pathol 2013;182:1092–1098.
   PubMed Web of Science ®Google Scholar
• Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111:800–805.
   PubMed Web of Science ®Google Scholar
• Wang X, Asplund AC, Porwit A, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008;143:248–252.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–1562.
   PubMed Web of Science ®Google Scholar
• Chen YH, Gao J, Fan G, et al. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010;23:105–112.
   PubMed Web of Science ®Google Scholar
• Meggendorfer M, Kern W, Haferlach C, et al. SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis. Leukemia 2013;27:2388–2391.
   PubMed Web of Science ®Google Scholar
• Dictor M, Ek S, Sundberg M, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt’s lymphoma. Haematologica 2009;94:1563–1568.
   PubMed Web of Science ®Google Scholar
• Soldini D, Valera A, Sole C, et al. Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am J Surg Pathol 2014;38:86–93.
   PubMed Web of Science ®Google Scholar
• Lefebvre V, Dumitriu B, Penzo-Mendez A, et al. Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 2007;39: 2195–2214.
   PubMed Web of Science ®Google Scholar
• Dy P, Penzo-Mendez A, Wang H, et al. The three SoxC– proteinsSox4, Sox11 and Sox12–exhibit overlapping expression patterns and molecular properties. Nucleic Acids Res 2008;36: 3101–3117.
   PubMed Web of Science ®Google Scholar
• Wasik AM, Lord M, Wang X, et al. SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression. Sci Rep 2013;3:1400.
   PubMed Web of Science ®Google Scholar
• Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Nygren L, Baumgartner Wennerholm S, Klimkowska M, et al.Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012;119:4215–4223.
   PubMed Web of Science ®Google Scholar
• Nordstrom L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma a Nordic Lymphoma Group study. Br J Haematol 2014.
   PubMed Web of Science ®Google Scholar
• Oinonen R, Franssila K, Teerenhovi L, et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329–336.
   PubMed Web of Science ®Google Scholar
• Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12:1281–1287.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012;26:1895–1898.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72:5307–5316.
   PubMed Web of Science ®Google Scholar